Drug Information

General Information
Drug ID
DR00510
Drug Name
Thioguanine
Synonyms
2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; BW 5071; DX4; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Guanine, thio-(VAN); LT00455187; Lanvis; Lanvis (TN); Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; THG; Tabloid; Thioguanin GSK; Thioguanin-GSK; ThioguaninGSK; Thioguanine (Guanine analog); Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Thioguanine [USAN:BAN]; Tioguanin; Tioguanina; Tioguanina Wellcome; Tioguanina[INN-Spanish]; Tioguanine; Tioguanine (INN); Tioguanine GlaxoSmithKline Brand; Tioguaninum; Tioguaninum [INN-Latin]; Wellcome Brand of Thioguanine; Wellcome U3B
Drug Type
Small molecular drug
Indication Acute myeloid leukemia [ICD11: 2A60] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C5H5N5S
Canonical SMILES
C1=NC2=C(N1)C(=S)N=C(N2)N
InChI
InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
InChIKey
WYWHKKSPHMUBEB-UHFFFAOYSA-N
CAS Number
CAS 154-42-7
Pharmaceutical Properties Molecular Weight 167.19 Topological Polar Surface Area 111
Heavy Atom Count 11 Rotatable Bond Count 0
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 2
XLogP
-0.1
PubChem CID
2723601
PubChem SID
11335603 , 11360842 , 11363129 , 11364886 , 11365691 , 11367448 , 11368253 , 11370010 , 11371594 , 11373049 , 11374590 , 11375610 , 11376415 , 11378179 , 11445995 , 11451636 , 11461814 , 11484585 , 11488511 , 11490393 , 11492741 , 11494049 , 14772534 , 15171129 , 16902289 , 23926847 , 24890748 , 24890892 , 26611944 , 26679349 , 26748270 , 26748271 , 26748272 , 30081936 , 3131990 , 37587702 , 4361010 , 4364659 , 46508170 , 47365125 , 48094105 , 48110398 , 48110399 , 538243 , 5646737 , 610358 , 6425700 , 7980774 , 8149552 , 9850
ChEBI ID
CHEBI:9555
TTD Drug ID
D02ZXM
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
CNT3 Transporter Info Concentrative Na(+)-nucleoside cotransporter 3 Substrate [3]
MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [4]
References
1 Thioguanine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
3 Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15.
4 Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.